Endoglin requirement for BMP9 signaling in endothelial cells reveals new mechanism of action for selective anti-endoglin antibodies.
about
Anti-angiogenic alternatives to VEGF blockadeTargeting BMP signalling in cardiovascular disease and anaemiaActivin A more prominently regulates muscle mass in primates than does GDF8.Modulation of circulating protein biomarkers following TRC105 (anti-endoglin antibody) treatment in patients with advanced cancer.Molecular pathways: can activin-like kinase pathway inhibition enhance the limited efficacy of VEGF inhibitors?Investigation of endoglin wild-type and missense mutant protein heterodimerisation using fluorescence microscopy based IF, BiFC and FRET analyses.Structural Basis of the Human Endoglin-BMP9 Interaction: Insights into BMP Signaling and HHT1Facilitation of endoglin-targeting cancer therapy by development/utilization of a novel genetically engineered mouse model expressing humanized endoglin (CD105)An open-label phase Ib dose-escalation study of TRC105 (anti-endoglin antibody) with bevacizumab in patients with advanced cancer.A phase II study of TRC105 in patients with hepatocellular carcinoma who have progressed on sorafenibInhibition of ALK1 signaling with dalantercept combined with VEGFR TKI leads to tumor stasis in renal cell carcinoma.Antibody-directed coupling of endoglin and MMP-14 is a key mechanism for endoglin shedding and deregulation of TGF-β signaling.Endoglin for targeted cancer treatment.Potential roles of bone morphogenetic protein (BMP)-9 in human liver diseases.The role of BMPs in endothelial cell function and dysfunction.TGF-β & BMP receptors endoglin and ALK1: overview of their functional role and status as antiangiogenic targets.Emerging roles of BMP9 and BMP10 in hereditary hemorrhagic telangiectasia.Arteriovenous malformations in hereditary haemorrhagic telangiectasia: looking beyond ALK1-NOTCH interactions.Circulating CD105 shows significant impact in patients of oral cancer and promotes malignancy of cancer cells via CCL20.Functional analysis of endoglin mutations from hereditary hemorrhagic telangiectasia type 1 patients reveals different mechanisms for endoglin loss of function.The role of endoglin in post-ischemic revascularization.Endoglin-based biological therapy in the treatment of angiogenesis-dependent pathologies.Endoglin targeting inhibits tumor angiogenesis and metastatic spread in breast cancer.A phase I study of TRC105 anti-endoglin (CD105) antibody in metastatic castration-resistant prostate cancer.Anti-angiogenic agents for the treatment of solid tumors: Potential pathways, therapy and current strategies - A review.Effects of the combination of TRC105 and bevacizumab on endothelial cell biology.ENDOGLIN is dispensable for vasculogenesis, but required for vascular endothelial growth factor-induced angiogenesis.Compound genetically engineered mouse models of cancer reveal dual targeting of ALK1 and endoglin as a synergistic opportunity to impinge on angiogenic TGF-β signaling.Dynamic regulation of canonical TGFβ signalling by endothelial transcription factor ERG protects from liver fibrogenesis.Bevacizumab alone or in combination with TRC105 for patients with refractory metastatic renal cell cancer.Bone Morphogenetic Protein 9 Reduces Cardiac Fibrosis and Improves Cardiac Function in Heart Failure.
P2860
Q26775947-897FF4BB-BD7B-4103-82F2-ED7091A1945AQ26783734-858ADA9D-5364-48F9-A3CD-4DA563BD2367Q33630598-1ED0230D-8D6F-4517-8B4A-814E4C3140E1Q33913556-A20CFFE2-FEF7-456A-9E2F-1517FC083315Q33957962-2F8695E1-F731-4EE9-841E-468F113001A7Q33981941-B1EDCBD6-F139-4FB2-8545-2D9F0261E6EDQ34557333-C62732CF-A8EC-4E39-B81A-085764A75270Q35158941-6E6E5A2E-C11C-44C0-8A24-F6C3DA1CAFD3Q36061812-908BD808-2A9D-4C80-B5F7-F86C6DE545C8Q36223538-6EB7C94E-ACEA-46FC-B61D-B46B6C0FDEF1Q37520379-E5EEF87F-EFFC-4F0F-80B6-6F41EC4CF17AQ37672682-83358723-E0AD-4AB2-9B78-215875EABA30Q38180309-85B508E5-7B7B-4FBB-8ADD-D76169CCB7E5Q38199567-7B068D0B-F618-4D6E-823C-B17707FEED02Q38218507-0CE529FF-BB4D-45E7-B96B-C9EEB0DE02FFQ38256407-BC89B9D7-7005-44A7-871F-4A7566D11732Q38332401-55A1CCE2-88E9-4914-A655-2B98A53A4EC2Q38662338-DC497AA5-5B8B-4082-98A9-FA44BFF4BFA1Q38838413-B1DD4918-50B3-4D14-8ECB-3F4C023A6087Q38948191-1BAA9BAE-868D-4607-BEBF-513CB808061CQ39036151-59059DCC-B952-4F75-85E8-4C4398F9F190Q39401943-D0BB3585-8886-4F58-9570-9A3F63A4DA17Q40068276-15CC966A-79DC-44F1-BF10-836D8A174ADEQ40182500-E2DA7C58-1483-454C-A1E9-D5CEB48C0797Q41258130-68455600-E25D-4380-A405-712B82CB6A95Q41889215-02585238-26F3-4715-9EB1-A6E0ACE2E987Q41896516-0820D233-E044-4721-831C-E2BAAD521FF7Q41900072-1EDA9304-F7FC-42E8-9A58-1762D3CB13AEQ42375998-88F6CAE4-C00B-41A9-9529-B28ABD442415Q46290452-3611DF76-5753-49CB-8AD9-11022B8E483DQ52682504-405BC198-4519-4E80-A221-FAA83C16DD59
P2860
Endoglin requirement for BMP9 signaling in endothelial cells reveals new mechanism of action for selective anti-endoglin antibodies.
description
2012 nî lūn-bûn
@nan
2012 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Endoglin requirement for BMP9 ...... tive anti-endoglin antibodies.
@ast
Endoglin requirement for BMP9 ...... tive anti-endoglin antibodies.
@en
Endoglin requirement for BMP9 ...... tive anti-endoglin antibodies.
@nl
type
label
Endoglin requirement for BMP9 ...... tive anti-endoglin antibodies.
@ast
Endoglin requirement for BMP9 ...... tive anti-endoglin antibodies.
@en
Endoglin requirement for BMP9 ...... tive anti-endoglin antibodies.
@nl
prefLabel
Endoglin requirement for BMP9 ...... tive anti-endoglin antibodies.
@ast
Endoglin requirement for BMP9 ...... tive anti-endoglin antibodies.
@en
Endoglin requirement for BMP9 ...... tive anti-endoglin antibodies.
@nl
P2093
P2860
P1433
P1476
Endoglin requirement for BMP9 ...... tive anti-endoglin antibodies.
@en
P2093
Astrid Ruefli-Brasse
Dineli Wickramasinghe
Joseph Hoover
Kathy Shaffer
Olivier Nolan-Stevaux
Stacey Culp
Wendy Zhong
P2860
P304
P356
10.1371/JOURNAL.PONE.0050920
P407
P577
2012-12-27T00:00:00Z